Intervention

MK0767

ClinicalTrials.gov intervention label

Clinical trials9

Recruiting0

Common conditions5

Lead sponsors shown1

Clinical trials

9 shown

MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)NCT00543816 · 2003-08-01

Dyslipidemia in Type 2 Diabetes (0767-034)NCT00547274 · 2003-07-01

MK0767 and Metformin Combination Study (0767-028)NCT00543738 · 2003-06-01

Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)NCT00543361 · 2003-05-01

MK0767 and Sulfonylurea Combination Study (0767-027)NCT00543491 · 2003-05-01

Study A - MK0767 Monotherapy StudyNCT00543517 · 2003-02-01

Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)NCT00543751 · 2003-01-01

MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)NCT00543010 · 2002-11-01

MK0767 in Type 2 Diabetes (0767-012)NCT00543556 · 2001-10-01

Common conditions

Diabetes Mellitus, Type 26 Diabetes Mellitus1 Diabetes Mellitus, Type II1 Dyslipidemia1 Type 2 Diabetes Mellitus1

Leading sponsors

Merck Sharp & Dohme LLC9

Trial status mix

TERMINATED9

Phase mix

PHASE38

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.